MCID: GLC086
MIFTS: 43

Glucocorticoid-Induced Osteoporosis

Categories: Bone diseases

Aliases & Classifications for Glucocorticoid-Induced Osteoporosis

MalaCards integrated aliases for Glucocorticoid-Induced Osteoporosis:

Name: Glucocorticoid-Induced Osteoporosis 12 15
Steroid-Induced Osteoporosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060343

Summaries for Glucocorticoid-Induced Osteoporosis

Disease Ontology : 12 An osteoporosis caused by chronic glucocorticoid use. Glucocorticoids impair the replication, differentiation and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes; the also favor osteoclastogenesis leading to an increase in bone resorption.

MalaCards based summary : Glucocorticoid-Induced Osteoporosis, also known as steroid-induced osteoporosis, is related to rickets and secondary hyperparathyroidism. An important gene associated with Glucocorticoid-Induced Osteoporosis is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are Pathways in cancer and Mesodermal Commitment Pathway. The drugs Risedronate and Teriparatide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are cellular and growth/size/body region

Wikipedia : 74 Steroid-induced osteoporosis is osteoporosis arising due to use of glucocorticoids (steroid hormones) -... more...

Related Diseases for Glucocorticoid-Induced Osteoporosis

Diseases related to Glucocorticoid-Induced Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 rickets 30.5 VDR PTH BGLAP
2 secondary hyperparathyroidism 30.4 VDR TNFRSF11B PTH CALCA BGLAP ACP5
3 osteomalacia 30.3 VDR PTH CALCA BGLAP
4 hyperparathyroidism 30.3 VDR TNFSF11 TNFRSF11B PTH CALCA BGLAP
5 hypervitaminosis d 30.2 VDR PTH CALCA
6 synovitis 30.2 TNFSF11 TNFRSF11B ACP5
7 arthropathy 30.2 TNFSF11 TNFRSF11B IGF1
8 periodontitis 30.0 VDR TNFSF11 RUNX2 BGLAP ACP5
9 arthritis 30.0 TNFSF11 PTH FOS CSF1 ACP5
10 rheumatoid arthritis 29.9 TNFSF11 TNFRSF11B PTH FOS CSF1 BGLAP
11 connective tissue disease 29.9 TNFSF11 RUNX2 PTH CALCA BGLAP ACP5
12 osteomyelitis 29.9 TNFSF11 CALCA BMP2 ACP5
13 sclerosteosis 29.8 VDR TNFSF11 SFRP1 RUNX2 PTH DKK1
14 hyperthyroidism 29.7 PTH IGF1 CALCA BGLAP ACP5
15 primary hyperparathyroidism 29.6 VDR TNFSF11 PTH IGF1 CALCA BGLAP
16 osteonecrosis 29.4 TNFSF11 TNFRSF11B RUNX2 PTH IGF1 DKK1
17 bone resorption disease 29.2 VDR TNFSF11 TNFRSF11B RUNX2 PTH IGF1
18 osteopetrosis 29.1 TNFSF11 TNFRSF11B RUNX2 FOS CSF1 CALCA
19 osteogenic sarcoma 29.1 TNFSF11 TNFRSF11B RUNX2 PTH IGF1 FOS
20 chronic kidney disease 29.0 VDR TNFSF11 TNFRSF11B RUNX2 PTH IGF1
21 bone disease 28.8 VDR TNFSF11 TNFRSF11B RUNX2 PTH IGF1
22 osteoporosis 28.0 VDR TSC22D3 TNFSF11 TNFRSF11B SFRP1 RUNX2
23 bone mineral density quantitative trait locus 8 11.4
24 bone mineral density quantitative trait locus 15 11.4
25 triiodothyronine receptor auxiliary protein 10.6
26 hypogonadism 10.5
27 temporal arteritis 10.4
28 polyarticular onset juvenile idiopathic arthritis 10.4 TNFSF11 TNFRSF11B
29 hemophilic arthropathy 10.3 TNFSF11 TNFRSF11B
30 periodontitis, chronic 10.3 TNFSF11 TNFRSF11B
31 disseminated chorioretinitis 10.3 TNFSF11 TNFRSF11B
32 substernal goiter 10.3 PTH CALCA
33 bone giant cell sarcoma 10.3 TNFSF11 CSF1
34 back pain 10.3
35 paget disease of bone 5, juvenile-onset 10.3 TNFSF11 TNFRSF11B CALCA
36 aneurysmal bone cysts 10.3 TNFSF11 CALCA
37 chronic apical periodontitis 10.3 TNFSF11 TNFRSF11B
38 kummell's disease 10.3 TNFSF11 DKK1 CALCA
39 villonodular synovitis 10.3 CSF1 ACP5
40 multicentric reticulohistiocytosis 10.3 TNFSF11 TNFRSF11B CSF1
41 malignant ovarian brenner tumor 10.3 TNFSF11 PTH CALCA
42 bone mineral density quantitative trait locus 3 10.3
43 inflammatory bowel disease 10.3
44 sclerosteosis 1 10.2 DKK1 BGLAP
45 osteitis fibrosa 10.2 PTH CALCA BGLAP
46 gorham's disease 10.2 TNFSF11 PTH CALCA
47 nontoxic goiter 10.2 PTH CALCA BGLAP
48 idiopathic hypercalciuria 10.2 VDR TNFSF11 BGLAP
49 giant cell reparative granuloma 10.2 TNFSF11 PTH CALCA
50 chondrodysplasia, blomstrand type 10.2 TNFSF11 PTH BGLAP

Graphical network of the top 20 diseases related to Glucocorticoid-Induced Osteoporosis:



Diseases related to Glucocorticoid-Induced Osteoporosis

Symptoms & Phenotypes for Glucocorticoid-Induced Osteoporosis

MGI Mouse Phenotypes related to Glucocorticoid-Induced Osteoporosis:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 AXIN2 BGLAP BMP2 CSF1 DKK1 FOS
2 growth/size/body region MP:0005378 10.37 AXIN2 BMP2 CSF1 DKK1 FOS FOXO1
3 craniofacial MP:0005382 10.34 AXIN2 BMP2 CSF1 DKK1 FOS FOXO1
4 cardiovascular system MP:0005385 10.33 AXIN2 BMP2 CSF1 FOS FOXO1 IGF1
5 hematopoietic system MP:0005397 10.3 BGLAP BMP2 CSF1 FOS FOXO1 IGF1
6 endocrine/exocrine gland MP:0005379 10.29 AXIN2 BGLAP CSF1 FOS FOXO1 IGF1
7 homeostasis/metabolism MP:0005376 10.28 BGLAP BMP2 CSF1 DKK1 FOS FOXO1
8 immune system MP:0005387 10.25 BGLAP BMP2 CSF1 FOS FOXO1 IGF1
9 limbs/digits/tail MP:0005371 10.18 AXIN2 BMP2 CSF1 DKK1 FOS FOXO1
10 mortality/aging MP:0010768 10.17 AXIN2 BMP2 CSF1 DKK1 FOS FOXO1
11 hearing/vestibular/ear MP:0005377 10.08 AXIN2 BMP2 CSF1 FOS IGF1 PAX5
12 nervous system MP:0003631 10 AXIN2 BMP2 CSF1 DKK1 FOS FOXO1
13 reproductive system MP:0005389 9.73 AXIN2 BGLAP BMP2 CSF1 FOS FOXO1
14 no phenotypic analysis MP:0003012 9.7 AXIN2 CSF1 FOXO1 RUNX2 SFRP1 TNFSF11
15 skeleton MP:0005390 9.5 AXIN2 BGLAP BMP2 CSF1 DKK1 FOS

Drugs & Therapeutics for Glucocorticoid-Induced Osteoporosis

Drugs for Glucocorticoid-Induced Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
2
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
3
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
6
Denosumab Approved Phase 4 615258-40-7
7
Zoledronic Acid Approved Phase 4 118072-93-8 68740
8
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
9 Micronutrients Phase 4
10 Trace Elements Phase 4
11 Vitamins Phase 4
12 Hydroxycholecalciferols Phase 4
13 Nutrients Phase 4
14 Diphosphonates Phase 4
15 Hormones Phase 4
16 Calcium, Dietary Phase 4
17 Hormone Antagonists Phase 4
18 calcium channel blockers Phase 4
19 Ibandronic Acid Phase 4
20
Calcium Nutraceutical Phase 4 7440-70-2 271
21
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 6221 5280795
22
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
23
Genistein Investigational Phase 2, Phase 3 446-72-0 5280961
24 Protective Agents Phase 2, Phase 3
25 Estrogens Phase 2, Phase 3
26 Phytoestrogens Phase 2, Phase 3
27 Protein Kinase Inhibitors Phase 2, Phase 3
28 Calciferol Phase 3
29 Immunoglobulins Phase 3
30 Antibodies Phase 3
31 Antibodies, Monoclonal Phase 3
32
Pamidronate Approved Phase 1, Phase 2 40391-99-9 4674
33 glucocorticoids Phase 1, Phase 2
34
Tramadol Approved, Investigational 27203-92-5 33741
35
Morphine Approved, Investigational 57-27-2 5288826
36
Prednisolone Approved, Vet_approved 50-24-8 5755
37 Prednisolone acetate Approved, Vet_approved 52-21-1
38
Prednisolone phosphate Approved, Vet_approved 302-25-0
39
Methylprednisolone Approved, Vet_approved 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved 2921-57-5
41
Eldecalcitol Investigational 104121-92-8
42
Prednisolone hemisuccinate Experimental 2920-86-7
43 Estrogen Antagonists
44 Estrogen Receptor Antagonists
45 Raloxifene Hydrochloride
46 Estrogen Receptor Modulators
47 Anesthetics
48 Anti-Inflammatory Agents, Non-Steroidal
49 Analgesics
50 Polymethyl Methacrylate

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis? Completed NCT00221299 Phase 4 Risedronate;Parathyroid Hormone
2 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
3 A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women Completed NCT00545051 Phase 4 Placebo;ibandronate
4 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
5 Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial Recruiting NCT04091243 Phase 4 Romosozumab
6 Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study Recruiting NCT04177940 Phase 4 DMAB Discontinuation and Switching
7 Metabolic, Endocrine, and Central Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis Unknown status NCT03040531 Phase 2, Phase 3 Alendronate Oral Tablet
8 Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
9 Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis Completed NCT00051558 Phase 3 Teriparatide;Alendronate Sodium;Placebo;Placebo
10 Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men Completed NCT00503399 Phase 3 Teriparatide;Risedronate
11 A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis Recruiting NCT03164928 Phase 3 Denosumab
12 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
13 Can PTH Reverse Glucocorticoid-induced Osteoporosis Completed NCT00004993 Phase 2 Parathyroid hormone (hPTH 1-34)
14 Prevention of Steroid-Induced Osteoporosis in Children Terminated NCT00022841 Phase 1, Phase 2 Pamidronate
15 Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol Unknown status NCT01974167 Eldecalcitol;Alfacalcidol
16 Clinical Trial on the Efficacy of Raloxifene on Disease Activity and Glucocorticoid-induced Osteoporosis in Postmenopausal Women With Rheumatoid Arthritis Unknown status NCT02982083 Raloxifene hydrochloride;Placebo Oral Tablet
17 Percutaneous Vertebroplasty Versus Conservative Treatment in Vertebral Compression Fracture Associated With Glucocorticoids-induced Osteoporosis: a Prospective Cohort Study Unknown status NCT03330340
18 Steroid Induced Osteoporosis in the Pediatric Population Ancillary Study- Osteonecrosis in Children With Acute Lymphoblastic Leukemia Unknown status NCT01104324
19 Prospective,Non-interventional Study Investigating Possible Correlation Between Adherence to Postmenopausal and Steroid Induced Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication Completed NCT02472782 Teriparatide
20 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS) Completed NCT01663129
21 Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids Recruiting NCT02719314 Glucocorticoid treatment

Search NIH Clinical Center for Glucocorticoid-Induced Osteoporosis

Genetic Tests for Glucocorticoid-Induced Osteoporosis

Anatomical Context for Glucocorticoid-Induced Osteoporosis

MalaCards organs/tissues related to Glucocorticoid-Induced Osteoporosis:

40
Bone, Bone Marrow, Kidney, Heart, Liver, Endothelial, Appendix

Publications for Glucocorticoid-Induced Osteoporosis

Articles related to Glucocorticoid-Induced Osteoporosis:

(show top 50) (show all 1257)
# Title Authors PMID Year
1
Sodium hydrosulfide alleviates dexamethasone-induced cell senescence and dysfunction through targeting the miR-22/sirt1 pathway in osteoblastic MC3T3-E1 cells. 61
33603846 2021
2
Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro. 61
33564917 2021
3
Exosomes derived from vascular endothelial cells antagonize glucocorticoid-induced osteoporosis by inhibiting ferritinophagy with resultant limited ferroptosis of osteoblasts. 61
33590921 2021
4
TXNIP contributes to bone loss via promoting the mitochondrial oxidative phosphorylation during glucocorticoid-induced osteoporosis. 61
33347878 2021
5
A multiscale study of structural and compositional changes in a natural nanocomposite: Osteoporotic bone with chronic endogenous steroid excess. 61
33007528 2021
6
The effect of deer antler from East Kalimantan to increase trabecular bone density and calcium levels in serum on osteoporotic mice. 61
33580921 2021
7
Integrated renal metabolomic and metallomic profiling revealed protective effect and metabolic mechanism of Gushudan on glucocorticoid-induced osteoporotic rat based on GC-MS and ICP-MS. 61
33188945 2021
8
Glucocorticoid Receptor Regulates TNFSF11 Transcription by Binding to Glucocorticoid Responsive Element in TNFSF11 Proximal Promoter Region. 61
33494362 2021
9
Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. 61
33208241 2021
10
Therapies for Preventing Bone Loss with Glucocorticoid Treatment. 61
33409989 2021
11
[Chinese consensus on the prevention and treatment of glucocorticoid induced osteoporosis (2020)]. 61
33397016 2021
12
Practical Guidance for Prevention and Management of Glucocorticoid-Induced Osteoporosis for the Allergist/Immunologist. 61
33444813 2021
13
RANKL as a target for the treatment of osteoporosis. 61
33057808 2021
14
Topical Corticosteroids and Glucocorticoid-Induced Osteoporosis-Cumulative Dose and Duration Matter. 61
33471024 2021
15
Effects of mechanical stimuli on structure and organization of bone nanocomposites in rats with glucocorticoid-induced osteoporosis. 61
33600670 2021
16
Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. 61
32676524 2020
17
1H-NMR-based urinary metabolomic analysis for the preventive effects of gushudan on glucocorticoid-induced osteoporosis rats. 61
33075315 2020
18
Amniotic Fluid Stem Cell-Derived Extracellular Vesicles Counteract Steroid-Induced Osteoporosis In Vitro. 61
33375177 2020
19
The critical role of T cells in glucocorticoid-induced osteoporosis. 61
33414409 2020
20
Linking glucocorticoid-induced osteoporosis to osteoimmunology. 61
33311437 2020
21
Daphnetin ameliorates glucocorticoid-induced osteoporosis via activation of Wnt/GSK-3β/β-catenin signaling. 61
33171191 2020
22
Bone mineral density and trabecular bone score in patients with 21-hydroxylase deficiency after glucocorticoid treatment. 61
33301636 2020
23
Cycloastragenol protects against glucocorticoid-induced osteogenic differentiation inhibition by activating telomerase. 61
33165990 2020
24
Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines. 61
33317228 2020
25
Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. 61
33211212 2020
26
Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial. 61
32820698 2020
27
A chitosan film containing quercetin-loaded transfersomes for treatment of secondary osteoporosis. 61
31942700 2020
28
Novel osteoprotective nanocochleate formulation: A dual combination therapy-codelivery system against glucocorticoid induced osteoporosis. 61
32711046 2020
29
COL3A1, COL6A3, and SERPINH1 Are Related to Glucocorticoid-Induced Osteoporosis Occurrence According to Integrated Bioinformatics Analysis. 61
32999266 2020
30
Combined effect of teriparatide and an anti-RANKL monoclonal antibody on bone defect regeneration in mice with glucocorticoid-induced osteoporosis. 61
32645445 2020
31
High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. 61
32780152 2020
32
ACY‑1215, a HDAC6 inhibitor, decreases the dexamethasone‑induced suppression of osteogenesis in MC3T3‑E1 cells. 61
32705192 2020
33
Scavenging of Dickkopf-1 by macromer-based biomaterials covalently decorated with sulfated hyaluronan displays pro-osteogenic effects. 61
32673749 2020
34
Short communication: Dietary bovine milk-derived exosomes improve bone health in an osteoporosis-induced mouse model. 61
32622594 2020
35
Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. 61
32917834 2020
36
Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate. 61
32621924 2020
37
Gumi Bao decoction regulates bone metabolism-related mRNA expression in glucocorticoid-induced osteoporosis in rats. 61
33065783 2020
38
Transcriptome Analysis Reveals That Abeliophyllum distichum Nakai Extract Inhibits RANKL-Mediated Osteoclastogenensis Mainly Through Suppressing Nfatc1 Expression. 61
32781784 2020
39
Pinocembrin alleviates glucocorticoid-induced apoptosis by activating autophagy via suppressing the PI3K/Akt/mTOR pathway in osteocytes. 61
32470335 2020
40
Liquiritigenin reduces osteoclast activity in zebrafish model of glucocorticoid-induced osteoporosis. 61
32534995 2020
41
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. 61
32286516 2020
42
Investigation of dual-energy X-ray absorptiometry units necessary for pediatric rheumatologists in Japan and a proposal for shared access to equipment among hospitals. 61
32863346 2020
43
History of risedronate. 61
32387834 2020
44
Extraction, purification and anti-osteoporotic activity of a polysaccharide from Epimedium brevicornum Maxim. in vitro. 61
31751710 2020
45
Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway. 61
32377728 2020
46
Dexras1 plays a pivotal role in maintaining the equilibrium between adipogenesis and osteogenesis. 61
32335074 2020
47
Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. 61
32680651 2020
48
Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study. 61
32611386 2020
49
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. 61
31628810 2020
50
Correction to: Effects of short- and long-term glucocorticoid-induced osteoporosis on plasma metabolome and lipidome of ovariectomized sheep. 61
32727440 2020

Variations for Glucocorticoid-Induced Osteoporosis

Expression for Glucocorticoid-Induced Osteoporosis

Search GEO for disease gene expression data for Glucocorticoid-Induced Osteoporosis.

Pathways for Glucocorticoid-Induced Osteoporosis

Pathways related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1 12.69 IGF1 FOXO1 FOS BMP2 AXIN2
2
Show member pathways
12.39 SFRP1 FOXO1 DKK1 AXIN2
3
Show member pathways
12.3 TNFSF11 TNFRSF11B FOS ACP5
4 12.12 RUNX2 PAX5 IGF1 FOXO1
5 12.09 SFRP1 PAX5 DKK1 AXIN2
6 11.94 TNFSF11 TNFRSF11B FOS CSF1 ACP5
7 11.78 RUNX2 PTH IGF1 BMP2 BGLAP
8 11.76 RUNX2 FOXO1 FOS
9 11.73 TNFSF11 PTH FOS CSF1 ACP5
10
Show member pathways
11.69 TNFSF11 FOXO1 FOS
11 11.68 VDR RUNX2 FOXO1 FOS
12 11.66 VDR TNFSF11 RUNX2 PTH FOS BGLAP
13 11.54 RUNX2 PTH IGF1
14 11.44 TNFSF11 IGF1 DKK1 CSF1
15 11.36 RUNX2 FOS BGLAP
16 11.02 VDR TNFSF11 RUNX2 PTH FOS BGLAP
17 10.93 VDR TNFSF11 TNFRSF11B RUNX2 PTH IGF1
18 10.88 TNFSF11 IGF1 FOS CSF1 BMP2
19 10.86 TNFSF11 TNFRSF11B ACP5
20 10.77 TNFSF11 TNFRSF11B PTH BGLAP
21 10.71 RUNX2 CSF1
22 10.67 SFRP1 FOXO1 DKK1 BMP2
23 10.56 VDR PTH

GO Terms for Glucocorticoid-Induced Osteoporosis

Cellular components related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNFSF11 TNFRSF11B SFRP1 PTH IGF1 DKK1
2 extracellular space GO:0005615 9.36 TNFSF11 TNFRSF11B SFRP1 PTH MIR106B IGF1

Biological processes related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.19 VDR TSC22D3 RUNX2 PAX5 FOXO1 FOS
2 multicellular organism development GO:0007275 10.14 VDR TNFSF11 SFRP1 PAX5 DKK1 BMP2
3 positive regulation of transcription, DNA-templated GO:0045893 10.07 SFRP1 RUNX2 IGF1 FOXO1 FOS BMP2
4 cell differentiation GO:0030154 10.07 VDR TNFSF11 SFRP1 RUNX2 PAX5 FOXO1
5 negative regulation of transcription, DNA-templated GO:0045892 9.99 VDR SFRP1 RUNX2 FOXO1 CALCA BMP2
6 cytokine-mediated signaling pathway GO:0019221 9.97 TNFSF11 FOXO1 FOS CSF1
7 negative regulation of canonical Wnt signaling pathway GO:0090090 9.88 SFRP1 DKK1 BMP2 AXIN2
8 response to drug GO:0042493 9.88 TNFRSF11B SFRP1 PTH FOS BGLAP
9 aging GO:0007568 9.87 PAX5 FOS CALCA BGLAP
10 animal organ morphogenesis GO:0009887 9.86 VDR TNFSF11 PAX5 BMP2
11 cellular calcium ion homeostasis GO:0006874 9.85 VDR PTH CALCA
12 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 VDR TNFSF11 RUNX2 PTH PAX5 IGF1
13 positive regulation of osteoblast differentiation GO:0045669 9.8 RUNX2 IGF1 BMP2
14 negative regulation of gene expression GO:0010629 9.8 VDR SFRP1 PTH MIR106B IGF1 BMP2
15 positive regulation of gene expression GO:0010628 9.8 VDR TNFSF11 RUNX2 IGF1 DKK1 CSF1
16 cellular response to growth factor stimulus GO:0071363 9.79 SFRP1 BMP2 BGLAP
17 osteoblast differentiation GO:0001649 9.76 SFRP1 RUNX2 BMP2 BGLAP
18 bone mineralization GO:0030282 9.72 BMP2 BGLAP AXIN2
19 response to vitamin D GO:0033280 9.68 PTH BGLAP
20 osteoblast development GO:0002076 9.68 RUNX2 BGLAP
21 negative regulation of bone resorption GO:0045779 9.68 TNFRSF11B CALCA
22 positive regulation of ossification GO:0045778 9.67 PTH BMP2
23 positive regulation of glycogen biosynthetic process GO:0045725 9.67 PTH IGF1
24 cellular response to BMP stimulus GO:0071773 9.67 SFRP1 RUNX2 BMP2
25 negative regulation of peptidyl-tyrosine phosphorylation GO:0050732 9.66 SFRP1 MIR106B
26 regulation of osteoclast differentiation GO:0045670 9.66 TNFSF11 BGLAP
27 response to inorganic substance GO:0010035 9.65 TNFRSF11B BGLAP
28 cellular response to vitamin D GO:0071305 9.65 SFRP1 BGLAP
29 positive regulation of macrophage differentiation GO:0045651 9.64 CSF1 CALCA
30 regulation of ossification GO:0030278 9.64 RUNX2 CSF1
31 negative regulation of cardiac muscle cell differentiation GO:2000726 9.63 DKK1 BMP2
32 response to gravity GO:0009629 9.63 FOS BGLAP
33 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.62 RUNX2 BMP2
34 bone mineralization involved in bone maturation GO:0035630 9.61 IGF1 BMP2
35 bone resorption GO:0045453 9.61 TNFSF11 PTH ACP5
36 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.58 RUNX2 BMP2
37 positive regulation of osteoclast differentiation GO:0045672 9.58 TNFSF11 FOS CSF1
38 osteoclast proliferation GO:0002158 9.54 TNFSF11 CSF1
39 negative regulation of ossification GO:0030279 9.54 SFRP1 DKK1 CALCA
40 ossification GO:0001503 9.35 TNFSF11 RUNX2 BMP2 BGLAP ACP5
41 skeletal system development GO:0001501 9.17 VDR TNFRSF11B RUNX2 PTH IGF1 BMP2

Molecular functions related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 PTH IGF1 CALCA
2 cytokine activity GO:0005125 9.46 TNFSF11 TNFRSF11B CSF1 BMP2
3 DNA-binding transcription factor activity GO:0003700 9.43 VDR TSC22D3 RUNX2 PAX5 FOXO1 FOS
4 co-receptor binding GO:0039706 9.26 DKK1 BMP2
5 growth factor activity GO:0008083 8.92 IGF1 DKK1 CSF1 BMP2

Sources for Glucocorticoid-Induced Osteoporosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....